-
Kodak CEO Says Moving Forward On Generic Drug Ingredients Venture, With or Without Federal Loan
Monday, October 19, 2020 - 8:19pm | 448Read More...Eastman Kodak Co (NYSE: KODK) CEO Jim Continenza said Monday that the company would push ahead with making generic drug ingredients, irrespective of whether it receives government assistance or not, the Wall Street Journal reports. What Happened: “It was put on hold but we are...
-
US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case
Tuesday, August 25, 2020 - 9:42pm | 511Read More...The Department of Justice on Tuesday indicted Teva Pharmaceutical Industries Ltd’s (NYSE: TEVA) United States unit for conspiring to fix prices, rig bids, and colluding with other companies to allocate customers for generic drugs. What Happened: The indictment filed in the...
-
Teva CEO Kare Schultz On Drugmaker's Outlook, Coronavirus Response
Thursday, May 7, 2020 - 1:52pm | 479Read More...Generic drugmaker Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported a first-quarter earnings beat as the company managed to maintain business continuity, CEO Kare Schultz said on CNBC's "Squawk on the Street." Teva's 'Very Good' Quarter Teva is dedicated to...
-
Teva Plummets Amid Massive Price Fixing Accusations; Other Generic Drugmakers Also Fall
Monday, May 13, 2019 - 7:40am | 370Read More...Shares of generic and specialty medicines maker Teva Pharmaceutical Industries (NYSE: TEVA) fell more than 9 percent Monday morning in reaction to a lawsuit filed by 44 states. What Happened Teva, along with other global drug companies, is accused of conspiring to inflate the prices of their...
-
Baird: What Rite Aid's Renewed Deal With Distributor McKesson Means For Both Companies
Thursday, December 20, 2018 - 11:32am | 405Read More...Retail pharmacy chain Rite Aid Corporation (NYSE: RAD) announced a renewal of its contract Wednesday with pharmaceutical distributor McKesson Corporation (NYSE: MCK) through 2029. What Happened McKesson will continue sourcing and offering Rite Aid delivery of branded and generic drugs...
-
Global Appeal In A Generics ETF
Tuesday, January 30, 2018 - 11:53am | 469Read More...The health care sector, the third-largest sector weight in the S&P 500, is surging. Generic drugmakers have been a source of strength for the group. For example, the VanEck Vectors Generic Drugs ETF (NASDAQ: GNRX) is up 9 percent since the start of 2018 and resides near all-time highs after...
-
Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Wednesday, January 24, 2018 - 11:27am | 678Read More...Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...
-
Teva's Cost-Cutting Plan Nets A Mizuho Upgrade
Tuesday, January 9, 2018 - 10:56am | 455Read More...After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...
-
Mallinckrodt Sees Slight Positive From Tax Reform, Up To $500 Million Benefit
Friday, December 22, 2017 - 9:06am | 444Read More...Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Friday in an 8-K filing it expects to see an up to $500 million benefit from President Donald Trump's tax reform plan. What You Need To Know U.S. government officials passed this week the Tax Cut and Jobs Act and...
-
Goldman Sachs: Now Is The Time To Get In On Teva's Turnaround
Friday, December 15, 2017 - 11:01am | 331Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...
-
Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy
Friday, December 8, 2017 - 9:10am | 398Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the...
-
For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
Monday, November 13, 2017 - 12:48pm | 487Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...
-
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
Friday, November 10, 2017 - 2:22pm | 468Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO) impressed investors with third-quarter earnings Thursday and issued encouraging guidance that led some of Wall Street's bears to revisit their thesis on the pharmaceutical manufacturer. The Analyst RBC Capital Markets' Randall...
-
Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months
Friday, November 3, 2017 - 10:09am | 349Read More...Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...
-
Adamas Pharma's Gocovri Will Achieve 'Blockbuster' Status, Says Kerrisdale
Wednesday, November 1, 2017 - 10:29am | 438Read More...Adamas Pharmaceuticals Inc (NASDAQ: ADMS), a small-cap pharmaceutical company that develops therapies to treat chronic neurologic disorders, is a "misunderstood" stock that has a potential upside of four times, Kerrisdale Capital said in a new report. Adamas is expected to soon launch its first...
